SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study

MT Newswires Live

10/14

SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.

The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.

The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.

The firm expects to recruit all healthy subjects by November.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575215244"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575215244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575215244?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575215244","market":"hk","top_or_hot":-1,"title":"SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study","media":"MT Newswires Live","content":"<html><body><p> SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.</p><p>The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.</p><p>The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.</p><p>The firm expects to recruit all healthy subjects by November.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinoMab BioScience Doses First Group of Patients in Atopic Dermatitis Drug Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-14 21:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.</p><p>The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.</p><p>The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.</p><p>The firm expects to recruit all healthy subjects by November.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03681","symbol_name":"中國抗體-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575215244","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575215244","pubTimestamp":1760448084,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SinoMab BioScience  dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.The firm expects to recruit all healthy subjects by November.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03681":"中国抗体-B","BK1574":"生物医药B类股","BK1161":"生物科技"},"translate_title":"SinoMab BioScience对特应性皮炎药物研究中的第一组患者进行给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03681":1},"content_text":"SinoMab BioScience (HKG:3681) dosed the first cohort of healthy subjects in a Chinese bridging study of the subcutaneous formulation of atopic dermatitis drug SM17 on Tuesday, a same-day Hong Kong bourse filing said.The biopharmaceutical company said all subjects were well tolerated and there were no reports of adverse events.The bridging study aims to study the safety, tolerability, and pharmacokinetics profiles of SM17 administered subcutaneously and plans to enroll a total of 30 healthy subjects.The firm expects to recruit all healthy subjects by November.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}